Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.

Who May Be Eligible (Plain English)

Who May Qualify: - patients with pancreatic cancer who had undergone curative-intent surgery (R0 or R1 resection); - both sexes, age ≥18 years old; - ECOG performance status score ≤2; - the expected survival time was ≥3 months. Who Should NOT Join This Trial: - a known diagnosis of pancreatic cancer other than ductal adenocarcinoma; - treated with any systemic antitumor treatment before first-line chemotherapy onset; - died or lost to follow-up within one month after the initiation of adjuvant chemotherpay; - combined with other primary malignances. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * patients with pancreatic cancer who had undergone curative-intent surgery (R0 or R1 resection); * both sexes, age ≥18 years old; * ECOG performance status score ≤2; * the expected survival time was ≥3 months. Exclusion Criteria: * a known diagnosis of pancreatic cancer other than ductal adenocarcinoma; * treated with any systemic antitumor treatment before first-line chemotherapy onset; * died or lost to follow-up within one month after the initiation of adjuvant chemotherpay; * combined with other primary malignances.

Treatments Being Tested

DRUG

Later-line therapy

Another chemotherapy regimen, targeted therapy, or immunotherapy

Locations (1)

Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China